IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$38.45+1.09 (+2.92%)
Close on Nov 17, 2026Market cap $39.11MP/E –Yield –
IRulya Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
IRulya Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$46.92M. For fiscal 2025 it was -$41.43M. The highest annual figure on record is -$11.70M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.43M | – |
| FY2024 | Dec 31, 2024 | -$31.90M | – |
| FY2023 | Dec 31, 2023 | -$18.29M | – |
| FY2022 | Dec 31, 2022 | -$44.04M | – |
| FY2021 | Dec 31, 2021 | -$62.93M | – |
| FY2020 | Dec 31, 2020 | -$50.82M | – |
| FY2019 | Dec 31, 2019 | -$33.28M | – |
| FY2018 | Dec 31, 2018 | -$11.70M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.82M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.84M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.61M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.80M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.22M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.18M | – |
See a number that looks wrong?